Who are Lantus (glargine)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tresiba, Levemir, Apidra, Lantus, Novolog, Humalog.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lantus-glargine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lantus (glargine) — Competitive Intelligence Brief

Lantus (glargine) (Lantus (glargine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting basal insulin. Area: Diabetes.

phase 3 Long-acting basal insulin Insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Lantus (glargine) (Lantus (glargine)) — Massachusetts General Hospital. Lantus is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lantus (glargine) TARGET	Lantus (glargine)	Massachusetts General Hospital	phase 3	Long-acting basal insulin	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting basal insulin class)

Sanofi · 12 drugs in this class
Novo Nordisk A/S · 3 drugs in this class
Life for a Child Program, Diabetes Australia · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Providence Health & Services · 1 drug in this class
Rabin Medical Center · 1 drug in this class
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 drug in this class
University Hospital Tuebingen · 1 drug in this class
Gan and Lee Pharmaceuticals, USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lantus (glargine) — Competitive Intelligence Brief. https://druglandscape.com/ci/lantus-glargine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab